| KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy. | |
| | |
MedLine Citation:
|
PMID: 23208128 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: The prognostic and predictive value of KRAS mutations in patients with lung cancer is controversial. Biases in disease stage, treatment regimen, small-scale patient studies, and biomarker status have led to inconsistent results in previous reports. METHODS: The KRAS and EGFR genes were examined in 1935 consecutive patients with non-small cell lung cancer. All patients were divided into KRAS mutation (KRAS group), EGFR mutation (EGFR group), and KRAS/EGFR wild type (WT group) groups. Randomly selected cases were paired with patients with the KRAS mutation, the EGFR mutation, and KRAS/EGFR wild type patients according to tumor, node, metastasis stage, time of first visit within 1 year, and pathology. Progression-free survival (PFS) and overall survival were evaluated by Kaplan-Meier and Cox models. RESULTS: The KRAS mutation rate for lung adenocarcinoma was 5.90 %. The overall survival was 14.47, 20.57, and 42.73 months for the KRAS group, WT group, and EGFR group, respectively (P < 0.001). Multivariate analysis indicated that KRAS mutation status was an independent prognostic factor (hazard ratio 2.69, 95 % confidence interval 1.91-3.80, P < 0.001). No difference was found in PFS and tumor responsiveness between patients with a KRAS mutation and those with wild type KRAS/EGFR for chemotherapy and EGFR tyrosine kinase inhibitors (TKI). PFS did not significantly differ for chemotherapy among the three groups (P = 0.270). CONCLUSIONS: KRAS mutation is a poor prognosis factor, but it is not an independent predictor of response to EGFR-TKI or chemotherapy in patients with lung cancer. |
| | |
Authors:
|
Ji-Lin Guan; Wen-Zhao Zhong; She-Juan An; Jin-Ji Yang; Jian Su; Zhi-Hong Chen; Hong-Hong Yan; Zhi-Yong Chen; Zhi-Min Huang; Xu-Chao Zhang; Qiang Nie; Yi-Long Wu |
Related Documents
:
|
21755378 - A phase ii trial of neoadjuvant chemoradiation and local excision for t2n0 rectal cance... 16707528 - Vitreous relapse following primary chemotherapy for retinoblastoma: is adjuvant diode l... 23070108 - Survival after radiofrequency ablation in 122 patients with inoperable colorectal lung ... 23357968 - Reirradiation for locoregionally recurrent lung cancer: outcomes in small cell and non-... 14528078 - Aerosolized granulocyte macrophage colony-stimulating factor (gm-csf) therapy in metast... 18051798 - Adrenalectomy for metastatic adrenal tumors. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-12-4 |
Journal Detail:
|
Title: Annals of surgical oncology Volume: - ISSN: 1534-4681 ISO Abbreviation: Ann. Surg. Oncol. Publication Date: 2012 Dec |
Date Detail:
|
Created Date: 2012-12-4 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9420840 Medline TA: Ann Surg Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: External Validation of Extranodal Extension and Lymph Node Density as Predictors of Survival in Node...
Next Document: Factors Associated with Breast MRI Use: A Population-Based Analysis.